Cambridge Cognition develops computer-based cognitive tests used in academic research, pharmaceutical clinical trials, and early detection screening for conditions such as Alzheimer’s, depression, and ADHD. Spun out of Cambridge University in 2002, the company sells its products under the CANTAB brand. Sales have grown due to increasing demand in Europe and the US, where most of its clients are based, although the tests are conducted globally. Sales grew 40% a year, from £2.1m in 2008 to £5.9m in 2011, and the company is backed by Pall Mall Partners and YFM Equity Partners.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.